[Media Coverage] WIRED: “Reframing Futures of Global Health | Engineering Immunity” (Interview with Wataru Akahata)
An interview with Wataru Akahata, CEO of VLP Therapeutics (VLPT) and VLPT Japan, has been featured in the latest issue of WIRED magazine and on its online edition. "Vaccine development
[News Release] VLP Therapeutics Japan initiates Phase 1 clinical trial of T-cell inducing COVID-19 vaccine: advancing the development of a universal vaccine against multiple SARS-CoV-2 variants[News Release] VLP Therapeutics Japan initiates Phase 1 clinical trial of T-cell inducing COVID-19 vaccine: advancing the development of a universal vaccine against multiple SARS-CoV-2 variants
[News Release] VLP Therapeutics Japan initiates Phase 1 clinical trial of T-cell inducing COVID-19 vaccine: advancing the development of a universal vaccine against multiple SARS-CoV-2 variants
VLP Therapeutics Japan, Inc. (VLPT Japan), a Tokyo-based biotech company, announced on March 31 the initiation of a Phase 1 clinical trial in Japan for its COVID-19 vaccine (VLPCOV-U-01). VLPCOV-U-01
[News Release] VLP Therapeutics Japan reports safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base [iScience][News Release] VLP Therapeutics Japan reports safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base [iScience]
[News Release] VLP Therapeutics Japan reports safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base [iScience]
VLP Therapeutics Japan, Inc. (VLPT Japan) researchers and their colleagues at the National Institutes of Biomedical Innovation, Health and Nutrition (NIBN) in Japan published a paper in iScience online reporting
[News Release] VLP Therapeutics awarded US$ 2.8 million grant to develop novel malaria vaccines that improve protection, reduce costs, expand equitable access[News Release] VLP Therapeutics awarded US$ 2.8 million grant to develop novel malaria vaccines that improve protection, reduce costs, expand equitable access
[News Release] VLP Therapeutics awarded US$ 2.8 million grant to develop novel malaria vaccines that improve protection, reduce costs, expand equitable access
Maryland, US-based biotech company VLP Therapeutics, Inc. (VLPT) announced today that it has been awarded a two-year grant of over US$ 2.8 million (about JPY 433 million) from the Gates
- [News Release] VLPT, Boston U, NIH researchers harness 5-methylcytidine to fine-tune immune responses in replicon mRNA vaccines, paving the way for safer next-gen immunization [Science Translational Medicine]
[News Release] VLPT, Boston U, NIH researchers harness 5-methylcytidine to fine-tune immune responses in replicon mRNA vaccines, paving the way for safer next-gen immunization [Science Translational Medicine]
[News Release] VLPT, Boston U, NIH researchers harness 5-methylcytidine to fine-tune immune responses in replicon mRNA vaccines, paving the way for safer next-gen immunization [Science Translational Medicine]
VLP Therapeutics, Inc. (VLPT) researchers and their colleagues at Boston University and the National Institutes of Health (NIH) have demonstrated that incorporating a modified base known as 5-methylcytidine (5mC) into
[News Release] VLP Therapeutics Teams with Swedish AI Biotech Nygen Analytics on Vinnova-Funded Cancer Immunotherapy Research
Swedish-US partnership to develop predictive models that could transform personalized cancer treatment selection Gaithersburg, USA and LUND, Sweden, 11 November 2025 – Nygen Analytics AB, a pioneer in AI-powered single-cell